Skip to Content
Diagnosed with AS? Biologics can help >

Acetaminophen / hydrocodone Pregnancy and Breastfeeding Warnings

Acetaminophen / hydrocodone is also known as: Anexsia, Co-Gesic, Dolacet, Duocet, Hycet, Hydrocet, Hydrogesic, Liquicet, Lorcet, Lorcet 10/650, Lorcet HD, Lorcet Plus, Lortab, Maxidone, Norco, Stagesic, Theracodophen Low 90, Verdrocet, Vicodin, Vicodin ES, Vicodin HP, Xodol, Zamicet, Zydone, Zyfrel

Acetaminophen / hydrocodone Pregnancy Warnings

Benefit should outweigh risk US FDA pregnancy category: C Comments: -Prolonged use of opioids during pregnancy can result in physical dependence in the neonate; women should be advised of the risk of neonatal abstinence syndrome and ensure that appropriate treatment will be available. -Monitor neonates exposed to opioid analgesics for signs of excess sedation and respiratory depression.

Opioid analgesics cross the placenta. Hydrocodone use during labor may cause respiratory depression in the newborn infant. Prolonged use of opioids during pregnancy can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. The onset, duration, and severity of the condition will vary based on maternal use (duration of use, timing, and amount of last use) and rate of elimination in the newborn. There are no controlled data in human pregnancy. Chronic use of opioids may cause reduced fertility; it is unknown whether these effects are reversible. FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Acetaminophen / hydrocodone Breastfeeding Warnings

Breastfed infants of mothers who receive opioids, especially newborns, can experience drowsiness and CNS depression, even death. A study in 30 breastfeeding women found mean and median hydrocodone infant daily doses of 3.9 and 2.1 mcg/kg, respectively, which calculates to 2.4% and 1.6% of weight-adjusted maternal doses. Hydrocodone is metabolized to 6 active metabolites including hydromorphone. Mean and median hydromorphone daily doses of 2.1 and 0.3 mcg/kg, respectively, were found. Of interest was that 2 women excreted much more hydromorphone than others which might represent ultrarapid CYP450 2D6 metabolizers.

A decision should be made to discontinue breast-feeding or discontinue this drug, considering the importance of the drug to the mother Excreted into human milk: Yes (acetaminophen) Yes (hydrocodone) Comments: -Breastfed infants should be monitored for excess sedation and respiratory depression; immediate medical attention should be sought if infant develops breathing difficulties or limpness. -Withdrawal symptoms can occur in breastfed infants when maternal drug use or breastfeeding are stopped.

See references

References for pregnancy information

  1. "Product Information. Lortab (acetaminophen-hydrocodone)." Akorn Inc, Buffalo Grove, IL.
  2. "Product Information. Acetaminophen-Hydrocodone Bitartrate (acetaminophen-hydrocodone)." Mikart Inc, Atlanta, GA.
  3. "Product Information. Norco (acetaminophen-hydrocodone)." Allergan Inc, Irvine, CA.

References for breastfeeding information

  1. "Product Information. Acetaminophen-Hydrocodone Bitartrate (acetaminophen-hydrocodone)." Mikart Inc, Atlanta, GA.
  2. "Product Information. Norco (acetaminophen-hydrocodone)." Allergan Inc, Irvine, CA.
  3. "Product Information. Lortab (acetaminophen-hydrocodone)." Akorn Inc, Buffalo Grove, IL.
  4. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.